Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ViroMed of Korea Receives US Fast Track Status for Gene Therapy

publication date: May 19, 2016
Korea's ViroMed was granted Fast Track designation by the US FDA for VM202, a novel gene therapy scheduled to begin a US Phase II trial. VM202, ViroMed's lead drug candidate, will be tested in patients with Amyotrophic Lateral Sclerosis. In January, ViroMed published positive results from a US-Korea Phase II trial of VM202 in patients with critical limb ischemia. ViroMed said it would release data from a completed Phase I/II trial of VM202 in ALS patients later this year. More details....

Stock Symbol: (KOSDAQ:084990)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital